Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis - PubMed (original) (raw)
Review
Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis
Andrew Fernandez et al. Ocul Surf. 2022 Oct.
Abstract
Ocular allergy remains a significant burden to the population while the treatment for the severe, chronic forms of allergic conjunctivitis remains largely limited to non-specific immunosuppressants. Eosinophils are central to the pathophysiology and sustaining the immunologic response found in the chronic forms of ocular allergy such as vernal keratoconjunctivitis and atopic keratoconjunctivitis. Several mediators of eosinophil recruitment, chemotaxis, adhesion, activation, and survival have been identified that offer potential therapeutic targets for ocular allergy. Based on preclinical and clinical data available in both ocular and non-ocular allergy studies, these emerging therapies warrant further investigation in reducing the severity of disease in patients with chronic ocular allergy.
Keywords: AKC; Allergy; Conjunctivitis; Cornea; Eosinophil; Mediators; Treatment; VKC.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Authors have no conflicts of interest to disclose.
Similar articles
- Lirentelimab for severe and chronic forms of allergic conjunctivitis.
Anesi SD, Tauber J, Nguyen QD, Chang P, Berdy GJ, Lin CC, Chu DS, Levine HT, Fernandez AD, Roy N, Asbell PA, Kantor AM, Chang AT, Singh B, Youngblood BA, Jeng BH, Jhanji V, Rasmussen HS, Foster CS. Anesi SD, et al. J Allergy Clin Immunol. 2022 Sep;150(3):631-639. doi: 10.1016/j.jaci.2022.03.021. Epub 2022 Apr 4. J Allergy Clin Immunol. 2022. PMID: 35390403 Clinical Trial. - Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.
Mishra GP, Tamboli V, Jwala J, Mitra AK. Mishra GP, et al. Recent Pat Inflamm Allergy Drug Discov. 2011 Jan;5(1):26-36. doi: 10.2174/187221311794474883. Recent Pat Inflamm Allergy Drug Discov. 2011. PMID: 21171952 Free PMC article. Review. - Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases.
Hingorani M, Calder V, Jolly G, Buckley RJ, Lightman SL. Hingorani M, et al. J Allergy Clin Immunol. 1998 Nov;102(5):821-30. doi: 10.1016/s0091-6749(98)70023-5. J Allergy Clin Immunol. 1998. PMID: 9819300 - Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis.
Uchio E, Ono SY, Ikezawa Z, Ohno S. Uchio E, et al. Clin Exp Allergy. 2000 Jan;30(1):103-9. doi: 10.1046/j.1365-2222.2000.00699.x. Clin Exp Allergy. 2000. PMID: 10606937 - Ocular allergy test and biomarkers on the ocular surface: Clinical test for evaluating the ocular surface condition in allergic conjunctival diseases.
Shoji J. Shoji J. Allergol Int. 2020 Oct;69(4):496-504. doi: 10.1016/j.alit.2020.05.003. Epub 2020 Jun 17. Allergol Int. 2020. PMID: 32563624 Review.
Cited by
- Vernal Keratoconjunctivitis: A Systematic Review.
Bruschi G, Ghiglioni DG, Cozzi L, Osnaghi S, Viola F, Marchisio P. Bruschi G, et al. Clin Rev Allergy Immunol. 2023 Aug;65(2):277-329. doi: 10.1007/s12016-023-08970-4. Epub 2023 Sep 2. Clin Rev Allergy Immunol. 2023. PMID: 37658939 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources